Ranking the BEST Weight Loss Drugs (UPDATED)

How Do Today's Weight Loss Drugs Stack Up Against Each Other?

With so many weight loss medications on the market now, figuring out which one is worth your time, money, and potential side effects can feel overwhelming. Dr. Brian Yeung's video attempts to rank the current options, and while no single ranking system will work perfectly for everyone, this is a reasonable starting point for understanding the playing field.

The weight loss drug market has changed more in the last five years than it did in the previous thirty. We went from a handful of modest options like phentermine and orlistat to a new generation of GLP-1 receptor agonists that are producing results nobody thought possible with medication alone. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have essentially rewritten expectations for what prescription weight loss can look like. But that does not mean the older drugs are useless, and it does not mean the newest drugs are right for everyone.

The video does a good job of categorizing medications by mechanism. You have the GLP-1 receptor agonists, the dual and triple agonists, appetite suppressants like phentermine, fat absorption blockers like orlistat, and combination therapies. Each category works differently, has different side effect profiles, and suits different people depending on their medical history, budget, and goals.

The GLP-1 Tier: Why These Drugs Changed Everything

Semaglutide and tirzepatide sit at the top of most ranking systems for good reason. The clinical trial data is hard to argue with. Semaglutide at the 2.4mg weekly dose (Wegovy) produced an average of about 15% total body weight loss in the STEP trials. Tirzepatide pushed that even further, with the highest dose producing around 22% weight loss in the SURMOUNT trials. For context, most previous weight loss drugs were considered successful if they produced 5-7% weight loss.

But the video rightly points out that efficacy is only one factor. Cost is a massive consideration. Without insurance coverage, these medications can run $800-1500 per month. Even with insurance, copays can be prohibitive. And insurance coverage remains inconsistent, with many plans covering these drugs for diabetes but not for weight loss alone. This creates an unfair system where access depends heavily on your insurance plan and sometimes on whether your doctor is willing to get creative with diagnosis codes.

Side effects also matter in the ranking. GLP-1 medications are generally well-tolerated, but the GI effects (nausea, vomiting, constipation, diarrhea) are common enough that they cause some people to discontinue treatment. About 5-10% of clinical trial participants dropped out due to side effects. That is not a huge number, but it is real, and it is worth knowing going in.

What the Video Gets Right

The tiered ranking approach is sensible. Rather than declaring one drug the absolute best, the video acknowledges that individual factors like medical history, insurance coverage, and personal tolerance for side effects all influence which drug makes the most sense for a given person. This is exactly the right framing. A drug that is theoretically more effective but costs three times as much and is not covered by your insurance is not actually the best option for you.

The inclusion of older medications like phentermine is also welcome. These drugs tend to get dismissed in the GLP-1 era, but phentermine remains a viable short-term option for some people, especially when cost is a barrier to the newer medications. It is not a long-term solution and it comes with its own risks, including potential for dependency and cardiovascular effects, but pretending it does not exist is not helpful either.

What It Misses

The video could go deeper on the pipeline drugs. Retatrutide, survodutide, orforglipron (an oral GLP-1), and several others are in late-stage trials. While none of these are available yet, understanding what is coming helps people make better decisions about their current treatment plans. If you are about to commit to a two-year treatment course, knowing that potentially better options might be available in 12-18 months is relevant information.

The combination therapy discussion is also thin. Many obesity medicine specialists are combining medications, like low-dose phentermine with a GLP-1, to improve results while managing side effects. These combinations are off-label but increasingly common in clinical practice, and they deserve more than a passing mention.

There is also minimal discussion of what happens when you stop these medications. This is one of the biggest issues in the weight loss drug conversation right now. Studies show that most people regain a significant portion of the weight they lost within a year of stopping GLP-1 medications. This does not make the drugs useless, but it does reframe them as potentially long-term or even lifelong treatments rather than short-term fixes. That changes the cost calculation dramatically.

Questions to Bring to Your Doctor

If you are weighing your options, start by asking your doctor which medications your insurance actually covers. This single question will narrow your choices significantly. Then ask about your specific medical history. Some drugs are contraindicated with certain conditions. Phentermine, for instance, is not appropriate for people with uncontrolled hypertension or a history of heart disease. GLP-1 medications may not be ideal for people with a personal or family history of medullary thyroid carcinoma.

Ask about realistic expectations for weight loss with each option and the expected timeline. Ask about the plan for when and if you stop the medication. And ask about what lifestyle changes you should be making alongside the medication, because no drug works well in a vacuum. Exercise and dietary changes are still the foundation, and medication works best when layered on top of those habits.

The Real-World Access Problem

Clinical trial efficacy numbers are meaningless if you cannot get the medication. The access gap between what exists and what average patients can actually obtain is one of the biggest unresolved issues in obesity medicine today. Insurance formularies change quarterly. Prior authorization requirements vary wildly between carriers. Some plans cover GLP-1 medications for diabetes but categorically exclude them for weight loss, creating a perverse incentive for providers to emphasize diabetes diagnoses. Even with coverage, specialty pharmacy requirements and copay accumulators can create barriers that discourage all but the most persistent patients.

Compounded semaglutide and tirzepatide have entered this access conversation in a big way. While the FDA has cracked down on some compounding pharmacies, others continue to operate legally, offering these medications at a fraction of the brand-name price. The quality and safety of compounded medications is a legitimate concern. Not all compounding pharmacies are equal, and without the manufacturing controls of major pharmaceutical companies, there is inherent variability. But for many people, the choice is between compounded medication and no medication at all, which makes the theoretical risks of compounding a practical trade-off they are willing to make.

The international pharmacy route is another option that the video does not address. Some patients order medications from Canadian or European pharmacies where prices are significantly lower. The legal and safety implications of this approach vary, and the FDA officially discourages it, but the practice is widespread enough that any honest ranking should acknowledge that cost and access influence real-world outcomes as much as pharmacological potency does. A drug that produces 22% weight loss in trials but costs $1,500 per month produces 0% weight loss for someone who cannot afford it.

Looking at the competitive dynamics, pharmaceutical companies are racing to develop next-generation weight loss drugs. Oral formulations, longer-acting injectables, and multi-receptor agonists like retatrutide are all in the pipeline. This competition will eventually drive prices down and improve access. But for people who need help now, the current options and their practical accessibility are what matter, and any ranking system that ignores the access reality is giving you an incomplete picture of the treatment options that actually exist for real people with real budgets and real insurance plans.

One thing to keep in mind as you evaluate these drugs is that the clinical trial populations do not always look like you. Trial participants are screened for compliance, receive regular monitoring, and follow specific protocols that may not reflect real-world conditions. Real-world outcomes for any given drug tend to be somewhat lower than trial results, and the drug that performs best in a controlled setting is not always the drug that performs best in your specific life with your specific challenges and support system.

Who Should Watch This Video

Anyone who is in the early research phase of considering weight loss medication will find this useful. It gives you a framework for thinking about the options without being so technical that you need a medical degree to follow along. People who are already on a GLP-1 medication and curious about how it compares to alternatives will also get value here.

If you are looking for deep clinical data or nuanced discussion of trial endpoints, you will need to look elsewhere. This is more of an overview than a deep dive, and that is fine for what it is trying to do. Just know that this should be a starting point for your research, not the final word on which drug is right for you.